




**Reimbursement and regulatory issues aside, which treatment regimen is optimal for a patient (BRCA wild type) with ovarian cancer who experiences disease relapse 12 months after receiving adjuvant carboplatin/paclitaxel after debulking surgery?**




**Reimbursement and regulatory issues aside, which treatment regimen is optimal for a patient with ovarian cancer and a BRCA germline mutation who experiences disease relapse 12 months after receiving adjuvant carboplatin/paclitaxel after debulking surgery?**



## How would you indirectly compare olaparib, niraparib and rucaparib in terms of their efficacy?



## How would you indirectly compare olaparib, niraparib and rucaparib in terms of their general toxicity/tolerability?



**Regulatory and reimbursement issues aside, do you believe it is reasonable to offer a PARP inhibitor to a patient with a BRCA germline mutation who is s/p debulking surgery and at very high risk for recurrence (ie, persistent tumor marker elevation, suboptimal debulking)?**

Yes

89%



No

11%



**Regulatory and reimbursement issues aside, do you believe it is reasonable to administer a PARP inhibitor in combination with bevacizumab as maintenance therapy for a patient with advanced ovarian cancer?**

Yes

48%




No


52%



# Reimbursement and regulatory issues aside, what would be the optimal treatment approach for a patient with de novo metastatic triple-negative breast cancer (TNBC) and a BRCA germline mutation?




**Reimbursement and regulatory issues aside, what would be the optimal treatment approach for a patient with TNBC and a BRCA germline mutation with metastatic minimally symptomatic disease recurrence 8 months after receiving adjuvant anthracycline/taxane?**





# Reimbursement and regulatory issues aside, what would be the optimal treatment approach for an asymptomatic woman presenting de novo with metastatic ER-positive, HER2-negative breast cancer and a BRCA germline mutation?



**In general, what is the optimal approach to mutation testing for a patient with ovarian cancer who has just undergone initial debulking surgery and has no family history of breast or ovarian cancer?**

